 U.S. News & World Report | Safety Issue Halts Study of BMS HCV Drug MedPage Today Bristol-Myers Squibb has suspended treatment "to protect patient safety" in a phase IIb trial of an investigational oral drug for hepatitis C. A spokeswoman for the company said the decision was made after one of the patients getting 200 mg of the ... Bristol-Myers Halts Hepatitis C Study on Safety Issue Bristol-Myers exec charged with insider trading Bristol-Myers suspends hepatitis C treatment study, cites possible cardiac concern |
Thursday, August 2, 2012
Safety Issue Halts Study of BMS HCV Drug - MedPage Today
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment